Join us on January 29, 2020 at 11:00 AM EST for a webinar on Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies?
Hepatitis delta, a dangerous coinfection of hepatitis B, is estimated to affect between 15 and 70 million people across the world. For decades, the only treatment option has been pegylated interferon; an often difficult drug to tolerate with only a small chance of controlling liver disease. With many new drugs now in clinical trials for hepatitis delta, we must ask, what does successful treatment look like?
- How can we measure success?
- What does it mean to control hepatitis delta?
- Is a cure for hepatitis B the only ideal endpoint of treatment?
Join hepatitis delta expert, Dr. Ohad Etzion, as he outlines the challenges in controlling the disease, current clinical trials, and explores ideal endpoints for treatment and control of hepatitis B and delta coinfection.